| Date Filed | Type | Description |
| 07/09/2019 |
GN
| Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology |
| 07/09/2019 |
GN
| Nanobiotix annonce la publication dans le Lancet Oncology des données de phase III dans le Sarcome des Tissus Mous pour NBTXR3 son produit premier d'une nouvelle classe |
| 07/03/2019 |
GN
| MERGER ALERT – ORIT and NANO: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies |
| 07/01/2019 |
GN
| DNBF, RTEC, and SHRC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers |
| 07/01/2019 |
GN
| MERGER ALERT – DNBF, SHRC, and NANO: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies |
| 07/01/2019 |
GN
| Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval |
| 07/01/2019 |
GN
| Nanobiotix annonce une nouvelle équipe de direction à la suite de son autorisation de mise sur le marché européen |
| 06/24/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Nanometrics Incorporated with Rudolph Technologies, Inc. is Fair to NANO Shareholders |
| 06/24/2019 |
GN
| RUDOLPH TECHNOLOGIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger |
| 06/04/2019 |
GN
| NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL |
| 06/04/2019 |
GN
| Nanobiotix nomme un nouveau directeur médical à la suite de son autorisation de mise sur le marché européen |
| 05/28/2019 |
GN
| Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare |
| 05/28/2019 |
GN
| Nanobiotix annonce le lancement de Curadigm : une nouvelle plateforme de nanotechnologie dédiée à la santé |
| 04/10/2019 |
GN
| Nanometrics to Announce First Quarter Financial Results on April 30, 2019 |
| 04/09/2019 |
GN
| NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES |
| 04/09/2019 |
GN
| NANOBIOTIX LEVE ENVIRON 29,5 MILLIONS D'EUROS DANS LE CADRE D'UN PLACEMENT D'ACTIONS ORDINAIRES NOUVELLES |
| 04/08/2019 |
GN
| NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING |
| 04/08/2019 |
GN
| NANOBIOTIX LANCE UNE AUGMENTATION DE CAPITAL PAR CONSTRUCTION ACCELEREE D'UN LIVRE D'ORDRE |
| 04/04/2019 |
GN
| Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval |
| 04/04/2019 |
GN
| NANOBIOTIX ANNONCE LA TOUTE PREMIERE AUTORISATION DE MISE SUR LE MARCHÉ EUROPEEN D'UN RADIOENHANCER |
| 04/02/2019 |
GN
| Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer |
| 04/02/2019 |
GN
| Efficacité de la combinaison NBTXR3 (premier produit de sa classe), radiothérapie et immunothérapie avec anti-PD-1 démontrée dans le cancer du Poumon résistant dans des modèles précliniques in vivo |
| 03/26/2019 |
GN
| Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback |